{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T13:30:41Z","timestamp":1793021441108,"version":"4.5.0"},"reference-count":72,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI15\/00681"],"award-info":[{"award-number":["PI15\/00681"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI17\/00409"],"award-info":[{"award-number":["PI17\/00409"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI18\/00821"],"award-info":[{"award-number":["PI18\/00821"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012513","name":"CIBERCV","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012513","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010801","name":"Xunta de Galicia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010801","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Ministry of Science, Innovation and Universities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009664","name":"Spanish Society of Cardiology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.bcp.2019.113677","type":"journal-article","created":{"date-parts":[[2019,10,21]],"date-time":"2019-10-21T18:41:34Z","timestamp":1571683294000},"page":"113677","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":158,"special_numbering":"C","title":["Empagliflozin reduces the levels of CD36 and cardiotoxic lipids while improving autophagy in the hearts of Zucker diabetic fatty rats"],"prefix":"10.1016","volume":"170","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3089-0684","authenticated-orcid":false,"given":"Alana","family":"Arag\u00f3n-Herrera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3739-5806","authenticated-orcid":false,"given":"Sandra","family":"Feij\u00f3o-Band\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Otero Santiago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Barral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3674-3749","authenticated-orcid":false,"given":"Manuel","family":"Campos-Toimil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Gil-Longo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thiago M.","family":"Costa Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom\u00e1s","family":"Garc\u00eda-Caballero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Rodr\u00edguez-Segade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estefan\u00eda","family":"Taraz\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Rosell\u00f3-Llet\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4415-7160","authenticated-orcid":false,"given":"Manuel","family":"Portol\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7154-1328","authenticated-orcid":false,"given":"Oreste","family":"Gualillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Ram\u00f3n","family":"Gonz\u00e1lez-Juanatey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisca","family":"Lago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2019.113677_b0005","doi-asserted-by":"crossref","first-page":"717","DOI":"10.2337\/dc16-0041","article-title":"SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study","volume":"39","author":"Abdul-Ghani","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.bcp.2019.113677_b0010","first-page":"1843","article-title":"Single dose of empagliflozin increases in vivo cardiac energy status in diabetic db\/db mice","volume":"114","author":"Abdurrachim","year":"2018","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.bcp.2019.113677_b0015","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/dom.13536","article-title":"Empagliflozin reduces myocardial ketone utilization while preserving glucose utilization in diabetic hypertensive heart disease: a hyperpolarized (13) C magnetic resonance spectroscopy study","volume":"21","author":"Abdurrachim","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.bcp.2019.113677_b0020","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1021\/pr201223p","article-title":"Obesity-dependent metabolic signatures associated with nonalcoholic fatty liver disease progression","volume":"11","author":"Barr","year":"2012","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.bcp.2019.113677_b0025","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1113\/jphysiol.2013.270538","article-title":"Impairments in mitochondrial palmitoyl-CoA respiratory kinetics that precede development of diabetic cardiomyopathy are prevented by resveratrol in ZDF rats","volume":"592","author":"Beaudoin","year":"2014","journal-title":"J. Physiol."},{"key":"10.1016\/j.bcp.2019.113677_b0030","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1124\/jpet.116.235069","article-title":"Empagliflozin Protects against Diet-Induced NLRP-3 Inflammasome Activation and Lipid Accumulation","volume":"359","author":"Benetti","year":"2016","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcp.2019.113677_b0035","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/s41569-018-0044-6","article-title":"Metabolic remodelling in heart failure","volume":"15","author":"Bertero","year":"2018","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.bcp.2019.113677_b0040","doi-asserted-by":"crossref","first-page":"R1202","DOI":"10.1152\/ajpregu.90820.2008","article-title":"Cardiac and skeletal muscle fatty acid transport and transporters and triacylglycerol and fatty acid oxidation in lean and Zucker diabetic fatty rats","volume":"297","author":"Bonen","year":"2009","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"10.1016\/j.bcp.2019.113677_b0045","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0014-5793(01)02799-5","article-title":"NMR indirect detection of glutamate to measure citric acid cycle flux in the isolated perfused mouse heart","volume":"505","author":"Burgess","year":"2001","journal-title":"FEBS Lett."},{"key":"10.1016\/j.bcp.2019.113677_b0050","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1002\/1873-3468.12297","article-title":"Signaling pathways involved in cardiac energy metabolism","volume":"590","author":"Chanda","year":"2016","journal-title":"FEBS Lett."},{"key":"10.1016\/j.bcp.2019.113677_b0055","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/S0008-6363(02)00399-1","article-title":"Cardiac carbohydrate metabolism in Zucker diabetic fatty rats","volume":"55","author":"Chatham","year":"2002","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.bcp.2019.113677_b0060","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.tem.2015.07.006","article-title":"Ceramides - Lipotoxic Inducers of Metabolic Disorders","volume":"26","author":"Chaurasia","year":"2015","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.bcp.2019.113677_b0065","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1111\/bph.12856","article-title":"Experimental design and analysis and their reporting: new guidance for publication in BJP","volume":"172","author":"Curtis","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bcp.2019.113677_b0070","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ijcard.2017.05.032","article-title":"Sodium-dependent glucose transporters (SGLT) in human ischemic heart: a new potential pharmacological target","volume":"243","author":"Di Franco","year":"2017","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.bcp.2019.113677_b0075","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.jacbts.2016.06.009","article-title":"Evidence of Glycolysis Up-Regulation and Pyruvate Mitochondrial Oxidation Mismatch During Mechanical Unloading of the Failing Human Heart: Implications for Cardiac Reloading and Conditioning","volume":"1","author":"Diakos","year":"2016","journal-title":"JACC Basic Transl. Sci."},{"key":"10.1016\/j.bcp.2019.113677_b0080","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.2337\/db15-1356","article-title":"Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes","volume":"65","author":"Ferrannini","year":"2016","journal-title":"Diabetes"},{"key":"10.1016\/j.bcp.2019.113677_b0085","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.jacc.2017.11.022","article-title":"Cardiovascular Mortality Reduction With Empagliflozin in Patients With Type 2 Diabetes and Cardiovascular Disease","volume":"71","author":"Fitchett","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.bcp.2019.113677_b0090","article-title":"Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial","author":"Fitchett","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.bcp.2019.113677_b0095","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/s41467-017-02795-4","article-title":"AMPK activation counteracts cardiac hypertrophy by reducing O-GlcNAcylation","volume":"9","author":"G\u00e9linas","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2019.113677_b0100","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1161\/CIRCRESAHA.108.187427","article-title":"Autophagy in ischemic heart disease","volume":"104","author":"Gustafsson","year":"2009","journal-title":"Circ. Res."},{"key":"10.1016\/j.bcp.2019.113677_b0105","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s10557-017-6734-1","article-title":"Empagliflozin Improves Left Ventricular Diastolic Dysfunction in a Genetic Model of Type 2 Diabetes","volume":"31","author":"Hammoudi","year":"2017","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.bcp.2019.113677_b0110","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s00125-016-4158-2","article-title":"The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE \u2212\/\u2212 mice fed a western diet","volume":"60","author":"Han","year":"2017","journal-title":"Diabetologia"},{"key":"10.1016\/j.bcp.2019.113677_b0115","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.2337\/dbi18-0018","article-title":"Strong Heart, Low Ceramides","volume":"67","author":"Holland","year":"2018","journal-title":"Diabetes"},{"key":"10.1016\/j.bcp.2019.113677_b0120","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1002\/jmri.21481","article-title":"Reproducible MRI measurement of adipose tissue volumes in genetic and dietary rodent obesity models","volume":"28","author":"Johnson","year":"2008","journal-title":"J. Magn. Reson. Imaging"},{"key":"10.1016\/j.bcp.2019.113677_b0125","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s10741-017-9665-9","article-title":"Direct cardiovascular impact of SGLT2 inhibitors: mechanisms and effects","volume":"23","author":"Kaplan","year":"2018","journal-title":"Heart Fail. Rev."},{"key":"10.1016\/j.bcp.2019.113677_b0130","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1161\/CIRCULATIONAHA.117.029166","article-title":"Effect of Empagliflozin on the Metabolic Signature of Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease","volume":"136","author":"Kappel","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.bcp.2019.113677_b0135","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1161\/CIRCRESAHA.118.311371","article-title":"Heart Failure in Type 2 Diabetes Mellitus","volume":"124","author":"Kenny","year":"2019","journal-title":"Circ. Res."},{"key":"10.1016\/j.bcp.2019.113677_b0140","article-title":"Sodium-glucose cotransporter 2 inhibitors regulate ketone body metabolism via inter-organ crosstalk","author":"Kim","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.bcp.2019.113677_b0145","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.tem.2013.11.004","article-title":"Cardiomyocyte health: adapting to metabolic changes through autophagy","volume":"25","author":"Kubli","year":"2014","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.bcp.2019.113677_b0150","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.pharmthera.2013.04.003","article-title":"Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data","volume":"139","author":"Kurosaki","year":"2013","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2019.113677_b0155","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s12933-016-0473-7","article-title":"Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome","volume":"15","author":"Kusaka","year":"2016","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.bcp.2019.113677_b0160","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s12933-018-0745-5","article-title":"Potential mechanisms responsible for cardioprotective effects of sodium-glucose co-transporter 2 inhibitors","volume":"17","author":"Lahnwong","year":"2018","journal-title":"Cardiovasc. Diabeto."},{"key":"10.1016\/j.bcp.2019.113677_b0165","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1096\/fj.201700300R","article-title":"Lipotoxic very-long-chain ceramides cause mitochondrial dysfunction, oxidative stress, and cell death in cardiomyocytes","volume":"32","author":"Law","year":"2018","journal-title":"FASEB J."},{"key":"10.1016\/j.bcp.2019.113677_b0170","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1210\/en.2009-1205","article-title":"Des-acyl ghrelin has specific binding sites and different metabolic effects from ghrelin in cardiomyocytes","volume":"151","author":"Lear","year":"2010","journal-title":"Endocrinology"},{"key":"10.1016\/j.bcp.2019.113677_b0175","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1194\/jlr.M090969","article-title":"CD36 plays a negative role in the regulation of lipophagy in hepatocytes through an AMPK-dependent pathway","volume":"60","author":"Li","year":"2019","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.bcp.2019.113677_b0180","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s12933-014-0148-1","article-title":"Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice","volume":"13","author":"Lin","year":"2014","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.bcp.2019.113677_b0185","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.plefa.2016.06.002","article-title":"Molecular mechanism of lipid-induced cardiac insulin resistance and contractile dysfunction","volume":"136","author":"Liu","year":"2018","journal-title":"Prostaglandins Leukot. Essent. Fatty Acids"},{"key":"10.1016\/j.bcp.2019.113677_b0190","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1161\/CIRCRESAHA.114.305675","article-title":"Targeting microRNAs to limit myocardial lipid accumulation","volume":"116","author":"Lopaschuk","year":"2015","journal-title":"Circ. Res."},{"key":"10.1016\/j.bcp.2019.113677_b0195","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1007\/s00125-018-4663-6","article-title":"Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits","volume":"61","author":"Lupsa","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.bcp.2019.113677_b0200","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jprot.2015.01.019","article-title":"Enhancing metabolomics research through data mining","volume":"127","author":"Mart\u00ednez-Arranz","year":"2015","journal-title":"J. Proteomics"},{"key":"10.1016\/j.bcp.2019.113677_b0205","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.004007","article-title":"Effect of Sodium-Glucose Cotransport-2 Inhibitors on Blood Pressure in People With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of 43 Randomized Control Trials With 22 528 Patients","volume":"6","author":"Mazidi","year":"2017","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.bcp.2019.113677_b0210","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1161\/CIRCRESAHA.117.311002","article-title":"Cardiovascular Metabolomics","volume":"122","author":"McGarrah","year":"2018","journal-title":"Circ. Res."},{"key":"10.1016\/j.bcp.2019.113677_b0215","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/nrendo.2016.169","article-title":"Sphingolipids and phospholipids in insulin resistance and related metabolic disorders","volume":"13","author":"Meikle","year":"2017","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.bcp.2019.113677_b0220","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s00210-015-1134-1","article-title":"A comprehensive review of the pharmacodynamics of the SGLT2 inhibitor empagliflozin in animals and humans","volume":"388","author":"Michel","year":"2015","journal-title":"Naunyn Schmiedebergs Arch. Pharmaco."},{"key":"10.1016\/j.bcp.2019.113677_b0225","doi-asserted-by":"crossref","first-page":"72","DOI":"10.3389\/fendo.2017.00072","article-title":"Diabetic Cardiomyopathy: An Immunometabolic Perspective","volume":"8","author":"Mishra","year":"2017","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"10.1016\/j.bcp.2019.113677_b0230","doi-asserted-by":"crossref","DOI":"10.14814\/phy2.13741","article-title":"Empagliflozin normalizes the size and number of mitochondria and prevents reduction in mitochondrial size after myocardial infarction in diabetic hearts","volume":"6","author":"Mizuno","year":"2018","journal-title":"Physiol. Rep."},{"key":"10.1016\/j.bcp.2019.113677_b0235","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1124\/jpet.118.253666","article-title":"Empagliflozin, an SGLT2 inhibitor, reduced the mortality rate after acute myocardial infarction with modification of cardiac metabolomes and anti-oxidants in diabetic rats","volume":"368","author":"Oshima","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcp.2019.113677_b0240","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.2337\/db17-1195","article-title":"Cardiac Dysfunction and Metabolic Inflexibility in a Mouse Model of Diabetes Without Dyslipidemia","volume":"67","author":"Rohm","year":"2018","journal-title":"Diabetes"},{"key":"10.1016\/j.bcp.2019.113677_b0245","doi-asserted-by":"crossref","first-page":"E388","DOI":"10.1002\/oby.20229","article-title":"Quantification of total and visceral adipose tissue in fructose-fed rats using water-fat separated single echo MRI","volume":"21","author":"R\u00f6nn","year":"2013","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.bcp.2019.113677_b0250","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1161\/CIRCRESAHA.117.309633","article-title":"AMP-Activated Protein Kinase: An Ubiquitous Signaling Pathway With Key Roles in the Cardiovascular System","volume":"120","author":"Salt","year":"2017","journal-title":"Circ. Res."},{"key":"10.1016\/j.bcp.2019.113677_b0255","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1161\/CIRCRESAHA.116.306842","article-title":"Lipid Use and Misuse by the Heart","volume":"118","author":"Schulze","year":"2016","journal-title":"Circ. Res."},{"key":"10.1016\/j.bcp.2019.113677_b0260","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1093\/cvr\/cvn116","article-title":"Regulation of sarcolemmal glucose and fatty acid transporters in cardiac disease","volume":"79","author":"Schwenk","year":"2008","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.bcp.2019.113677_b0265","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1517\/14728222.2016.1168808","article-title":"Sodium glucose cotransporter SGLT1 as a therapeutic target in diabetes mellitus","volume":"20","author":"Song","year":"2016","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.bcp.2019.113677_b0270","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.molmet.2016.10.006","article-title":"Metabolomic profiling identifies potential pathways involved in the interaction of iron homeostasis with glucose metabolism","volume":"6","author":"Stechemesser","year":"2016","journal-title":"Mol. Metab."},{"key":"10.1016\/j.bcp.2019.113677_b0275","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/s41573-019-0019-2","article-title":"AMP-activated protein kinase: the current landscape for drug development","volume":"18","author":"Steinberg","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bcp.2019.113677_b0280","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.redox.2017.06.009","article-title":"The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats","volume":"13","author":"Steven","year":"2017","journal-title":"Redox Biol."},{"key":"10.1016\/j.bcp.2019.113677_b0285","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1074\/jbc.M117.812834","article-title":"Docosahexaenoic acid lowers cardiac mitochondrial enzyme activity by replacing linoleic acid in the phospholipidome","volume":"293","author":"Sullivan","year":"2018","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2019.113677_b0290","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.3389\/fphys.2018.01575","article-title":"Direct Cardiac Actions of Sodium Glucose Cotransporter 2 Inhibitors Target Pathogenic Mechanisms Underlying Heart Failure in Diabetic Patients","volume":"9","author":"Uthman","year":"2018","journal-title":"Front. Physiol."},{"issue":"8","key":"10.1016\/j.bcp.2019.113677_b0295","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1475-2840-8-39","article-title":"Altered myocardial substrate metabolism is associated with myocardial dysfunction in early diabetic cardiomyopathy in rats: studies using positron emission tomography","volume":"22","author":"van den Brom","year":"2009","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.bcp.2019.113677_b0300","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1007\/s00125-018-4670-7","article-title":"SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review","volume":"61","author":"Verma","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.bcp.2019.113677_b0305","article-title":"Empagliflozin increases cardiac energy production in diabetes","author":"Verma","year":"2018","journal-title":"J. Am. Coll. Cardiol. Basic. Trans. Sci."},{"key":"10.1016\/j.bcp.2019.113677_b0310","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1161\/CIRCRESAHA.117.312317","article-title":"AMPK\u03b12 Protects Against the Development of Heart Failure by Enhancing Mitophagy via PINK1 Phosphorylation","volume":"122","author":"Wang","year":"2018","journal-title":"Circ. Res."},{"key":"10.1016\/j.bcp.2019.113677_b0315","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1096\/fj.201801267RR","article-title":"CTRP13 inhibits atherosclerosis via autophagy-lysosome-dependent degradation of CD36","volume":"33","author":"Wang","year":"2019","journal-title":"FASEB J."},{"key":"10.1016\/j.bcp.2019.113677_b0320","article-title":"Beneficial effects of canagliflozin in combination with pioglitazone on insulin sensitivity in rodent models of obese type 2 diabetes","volume":"10","author":"Watanabe","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bcp.2019.113677_b0325","doi-asserted-by":"crossref","DOI":"10.1111\/apha.13074","article-title":"Autophagy-A key pathway for cardiac health and longevity","volume":"223","author":"Woodall","year":"2018","journal-title":"Acta Physiol (Oxf)"},{"key":"10.1016\/j.bcp.2019.113677_b0330","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ebiom.2017.05.028","article-title":"SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice","volume":"20","author":"Xu","year":"2017","journal-title":"EBioMedicine"},{"key":"10.1016\/j.bcp.2019.113677_b0335","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.biopha.2018.10.095","article-title":"Early administration of empagliflozin preserved heart function in cardiorenal syndrome in rat","volume":"109","author":"Yang","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bcp.2019.113677_b0340","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.mce.2017.03.029","article-title":"Liraglutide relieves myocardial damage by promoting autophagy via AMPK-mTOR signaling pathway in zucker diabetic fatty rat","volume":"448","author":"Zhang","year":"2017","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.bcp.2019.113677_b0345","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/jcb.10631","article-title":"Human cardiomyocytes express high level of Na+\/glucose cotransporter 1 (SGLT1)","volume":"90","author":"Zhou","year":"2003","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.bcp.2019.113677_b0350","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1159\/000475942","article-title":"The Sodium-Glucose Co-Transporter 2 Inhibitor, Empagliflozin, Protects against Diabetic Cardiomyopathy by Inhibition of the Endoplasmic Reticulum Stress Pathway","volume":"41","author":"Zhou","year":"2017","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.bcp.2019.113677_b0355","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s10557-018-6831-9","article-title":"Sitagliptin Protects Cardiac Function by Reducing Nitroxidative Stress and Promoting Autophagy in Zucker Diabetic Fatty (ZDF) Rats","volume":"32","author":"Zhou","year":"2018","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.bcp.2019.113677_b0360","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295219303764?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295219303764?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T13:07:25Z","timestamp":1757768845000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295219303764"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":72,"alternative-id":["S0006295219303764"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2019.113677","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Empagliflozin reduces the levels of CD36 and cardiotoxic lipids while improving autophagy in the hearts of Zucker diabetic fatty rats","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2019.113677","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"113677"}}